トランスサイレチンアミロイドーシス治療の世界市場：市場規模・シェア・動向分析 (治療法別・種類別・疾患別・流通チャネル別・地域別・セグメント別、2025年～2030年)

トランスサイレチンアミロイドーシス治療市場の成長と動向：

Grand View Research社の最新レポートによると、世界のトランスサイレチンアミロイドーシス治療の市場規模は、2030年までに165億3,000万米ドルに達すると予測されています。

同市場は2025年から2030年にかけてCAGR 13.9%で成長すると予測されています。トランスサイレチンアミロイドーシス治療市場は、主に支援的な償還プログラムの存在とアフリカ系米国人人口の増加によって牽引されています。アフリカ系米国人はATTRアミロイドーシスに罹患しやすいため、アフリカ系米国人の増加は、期間を通じて業界成長の触媒として機能しました。Val122Ileは、65歳以上の高齢者の心筋症につながる変異として、世界で最も多く見られます。さらに、このVal122Ile変異は世界のアフリカ系米国人集団の3%から4%に認められます。

新規診断技術および集学的治療アプローチの開発のための研究活動の増加は、トランスサイレチンアミロイドーシスの生存率の向上およびより良好な予後につながると予想されます。例えば、2019年11月、アミロイドーシス研究コンソーシアムは、患者の視点からトランスサイレチンアミロイドーシスの影響を理解し測定するための疾患特異的患者報告アウトカム (PRO) ツールを開発しました。このようなツールのイントロダクションは、疾患の複雑性と患者のニーズを理解することにより、新たな標的特異的薬剤の開発研究を後押しし、トランスサイレチンアミロイドーシス治療市場の機会を拡大します。

ATTRのような標的疾患や利用可能な治療法の長期的な利点に関する認識を高めるなど、主要企業が行う戦略的イニシアチブは、業界の成長を促進すると予想されます。例えば、2019年にファイザー社は世界心臓連盟と共同で「ハートヒーロー」キャンペーンを開始しました。このキャンペーンでは、ファイザー社がATTR-CMに関連する教育情報やリソースを患者や医師に提供しています。このようなキャンペーンにより、ATTR-CMの早期診断が促進され、長期的な治療率の向上が期待されます。

主要企業がCSR活動の一環として行っている無償医療提供の動きも、市場成長を促進すると予測されます。例えば、ファイザーの患者支援プログラムは、VYNDAMAXなどのファイザーの医薬品を対象となる患者に無料で提供しています。アミロイドーシスと診断された人々は、Vandalinkプラットフォームで登録することにより、このようなプログラムを利用することができます。このようなプログラムにより、医師がトランスサイレチンアミロイドーシス患者の薬物療法として本薬を患者に処方することが期待されます。

トランスサイレチンアミロイドーシス治療市場：分析概要

• 種類別では、この疾患の高い有病率と高齢者人口の増加により、2024年にはATTR-CMが主要シェアを占めています。ATTR-PNは予測期間を通じて最も速い成長率を示すと予想されます。このセグメントの成長は、強力なパイプラインの存在に起因しています。
• 治療法別では、世界の治療法の承認とATTR-CM治療の処方率の上昇により、2024年には標的治療分野が圧倒的なシェアを獲得します。
• 疾患タイプ別では、遺伝性トランスサイレチンアミロイドーシス分野が2024年に市場を独占しました。これは、パイプラインの成長とともに、医薬品開発を目指すさまざまな製薬企業間の戦略的提携が拡大しているためです。
• 流通チャネル別では、ほとんどの病院がトランスサイレチンアミロイドーシスの診断、研究、治療に取り組んでいるため、病院薬局が2024年に最大のシェアを獲得しました。
• 北米地域は、新薬処方の増加、適切な償還政策、同地域の高い治療率により、2024年に最大のシェアを占めました。
• 中東・アフリカ地域は予測期間を通じて最も速い成長率を示すと予想されています。このセグメントの成長は、ATTRアミロイドーシスの罹患率の増加に起因しています。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 トランスサイレチンアミロイドーシス治療市場：変動要因・傾向・範囲

• 市場連関の見通し
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因の分析
• ビジネス環境分析
  • 業界分析：ポーターのファイブフォース分析
  • PESTEL分析

第4章 トランスサイレチンアミロイドーシス治療市場：治療法別のビジネス分析

• 市場シェア：治療法別 (2024年・2030年)
• 治療法別ダッシュボード
• 市場規模の予測と動向分析：治療法別 (2018～2030年)
• 標的療法
• 支持療法
• パイプライン療法

第5章 トランスサイレチンアミロイドーシス治療市場：種類別のビジネス分析

• 市場シェア：種類別 (2024年・2030年)
• 種類別ダッシュボード
• 市場規模の予測と動向分析：種類別 (2018～2030年)
• ATTR多発神経障害 (ATTR-PN)
• ATTR心筋症 (ATTR-CM)

第6章 トランスサイレチンアミロイドーシス治療市場：疾患別のビジネス分析

• 市場シェア：疾患別 (2024年・2030年)
• 疾患別ダッシュボード
• 市場規模の予測と動向分析：疾患別 (2018～2030年)
• 遺伝性トランスサイレチンアミロイドーシス
• 野生型アミロイドーシス

第7章 トランスサイレチンアミロイドーシス治療市場：流通チャネル別のビジネス分析

• 市場シェア：流通チャネル別 (2024年・2030年)
• 流通チャネル別ダッシュボード
• 市場規模の予測と動向分析：流通チャネル別 (2018～2030年)
• 病院薬局
• 専門薬局
• 小売薬局
• オンライン薬局

第8章 トランスサイレチンアミロイドーシス治療市場：地域別の推定・動向分析

• 市場シェア：地域別 (2024年・2030年)
• 市場ダッシュボード：地域別
• 市場規模の予測と動向分析 (2018～2030年)
• 北米
  • 国別 (2018～2030年)
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 国別 (2018～2030年)
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • デンマーク
  • スウェーデン
• アジア太平洋
  • 国別 (2018～2030年)
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • 国別 (2018～2030年)
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 国別 (2018～2030年)
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 参入企業概要
• 企業の市場ポジション分析
• 企業分類
• 戦略マッピング
• 企業プロファイル/上場企業
  • Pfizer Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals
  • AstraZeneca
  • Akcea Therapeutics
  • BridgeBio Inc.
  • Intellia Therapeutics, Inc.
  • SOM BIOTECH
  • Oncopeptides AB
  • Takeda Pharmaceutical Company Limited

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 Global transthyretin amyloidosis treatment market, by region, 2018 - 2030 (USD Million)
• Table 4 Global transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 5 Global transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
• Table 6 Global transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
• Table 7 Global transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 8 North America transthyretin amyloidosis treatment market, by country, 2018 - 2030 (USD Million)
• Table 9 North America transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 10 North America transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
• Table 11 North America transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
• Table 12 North America transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 13 U.S. transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 14 U.S. transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
• Table 15 U.S. transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
• Table 16 U.S. transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 17 Canada transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 18 Canada transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
• Table 19 Canada transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
• Table 20 Canada transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 21 Mexico transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 22 Mexico transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
• Table 23 Mexico transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
• Table 24 Mexico transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 25 Europe transthyretin amyloidosis treatment market, by country, 2018 - 2030 (USD Million)
• Table 26 Europe transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 27 Europe transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
• Table 28 Europe transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
• Table 29 Europe transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 30 UK transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 31 UK transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
• Table 32 UK transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
• Table 33 UK transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 34 Germany transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 35 Germany transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
• Table 36 Germany transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
• Table 37 Germany transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 38 France transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 39 France transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
• Table 40 France transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
• Table 41 France transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 42 Italy transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 43 Italy transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
• Table 44 Italy transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
• Table 45 Italy transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 46 Spain transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 47 Spain transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
• Table 48 Spain transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
• Table 49 Spain transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 50 Denmark transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 51 Denmark transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
• Table 52 Denmark transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
• Table 53 Denmark transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 54 Sweden transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 55 Sweden transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
• Table 56 Sweden transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
• Table 57 Sweden transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 58 Norway transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 59 Norway transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
• Table 60 Norway transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
• Table 61 Norway transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 62 Asia Pacific transthyretin amyloidosis treatment market, by country, 2018 - 2030 (USD Million)
• Table 63 Asia Pacific transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 64 Asia Pacific transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
• Table 65 Asia Pacific transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
• Table 66 Asia Pacific transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 67 China transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 68 China transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
• Table 69 China transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
• Table 70 China transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 71 Japan transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 72 Japan transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
• Table 73 Japan transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
• Table 74 Japan transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 75 India transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 76 India transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
• Table 77 India transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
• Table 78 India transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 79 Australia transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 80 Australia transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
• Table 81 Australia transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
• Table 82 Australia transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 83 South Korea transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 84 South Korea transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
• Table 85 South Korea transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
• Table 86 South Korea transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 87 Thailand transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 88 Thailand transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
• Table 89 Thailand transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
• Table 90 Thailand transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 91 Latin America transthyretin amyloidosis treatment market, by country, 2018 - 2030 (USD Million)
• Table 92 Latin America transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 93 Latin America transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
• Table 94 Latin America transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
• Table 95 Latin America transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 96 Brazil transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 97 Brazil transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
• Table 98 Brazil transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
• Table 99 Brazil transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 100 Argentina transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 101 Argentina transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
• Table 102 Argentina transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
• Table 103 Argentina transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 104 Middle East & Africa Transthyretin amyloidosis treatment market, by country, 2018 - 2030 (USD Million)
• Table 105 Middle East & Africa transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 106 Middle East & Africa transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
• Table 107 Middle East & Africa transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
• Table 108 Middle East & Africa transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 109 South Africa transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 110 South Africa transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
• Table 111 South Africa transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
• Table 112 South Africa transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 113 Saudi Arabia transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 114 Saudi Arabia transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
• Table 115 Saudi Arabia transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
• Table 116 Saudi Arabia transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 117 UAE transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 118 UAE transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
• Table 119 UAE transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
• Table 120 UAE transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 121 Kuwait transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
• Table 122 Kuwait transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
• Table 123 Kuwait transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
• Table 124 Kuwait transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Transthyretin amyloidosis treatment market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Therapy and type outlook (USD Million)
• Fig. 10 Disease and distribution channel outlook (USD Million)
• Fig. 11 Competitive landscape
• Fig. 12 Transthyretin amyloidosis treatment market dynamics
• Fig. 13 Transthyretin amyloidosis treatment market: Porter's five forces analysis
• Fig. 14 Transthyretin amyloidosis treatment market: PESTLE analysis
• Fig. 15 Transthyretin amyloidosis treatment market: Therapy segment dashboard
• Fig. 16 Transthyretin amyloidosis treatment market: Therapy market share analysis, 2024 & 2030
• Fig. 17 Targeted therapy market, 2018 - 2030 (USD Million)
• Fig. 18 Vyndaqel/ Vyndamax market, 2018 - 2030 (USD Million)
• Fig. 19 Onpattro market, 2018 - 2030 (USD Million)
• Fig. 20 Amvuttra market, 2018 - 2030 (USD Million)
• Fig. 21 Tegsedi market, 2018 - 2030 (USD Million)
• Fig. 22 Wainua market, 2018 - 2030 (USD Million)
• Fig. 23 Supportive therapy market, 2018 - 2030 (USD Million)
• Fig. 24 Pipeline Therapy market, 2018 - 2030 (USD Million)
• Fig. 25 Transthyretin amyloidosis treatment market: Type segment dashboard
• Fig. 26 Transthyretin amyloidosis treatment market: Type market share analysis, 2024 & 2030
• Fig. 27 ATTR with Polyneuropathy (ATTR-PN) market, 2018 - 2030 (USD Million)
• Fig. 28 ATTR with Cardiomyopathy (ATTR-CM) market, 2018 - 2030 (USD Million)
• Fig. 29 Transthyretin amyloidosis treatment market: Disease segment dashboard
• Fig. 30 Transthyretin amyloidosis treatment market: Disease market share analysis, 2024 & 2030
• Fig. 31 Hereditary transthyretin amyloidosis market, 2018 - 2030 (USD Million)
• Fig. 32 Polyneuropathy market, 2018 - 2030 (USD Million)
• Fig. 33 Cardiomyopathy market, 2018 - 2030 (USD Million)
• Fig. 34 Mixed type market, 2018 - 2030 (USD Million)
• Fig. 35 Wild type amyloidosis market, 2018 - 2030 (USD Million)
• Fig. 36 Transthyretin amyloidosis treatment market: Distribution channel segment dashboard
• Fig. 37 Transthyretin amyloidosis treatment market: Distribution channel market share analysis, 2024 & 2030
• Fig. 38 Hospital pharmacies market, 2018 - 2030 (USD Million)
• Fig. 39 Specialty pharmacies market, 2018 - 2030 (USD Million)
• Fig. 40 Retail pharmacies market, 2018 - 2030 (USD Million)
• Fig. 41 Online pharmacies market, 2018 - 2030 (USD Million)
• Fig. 42 Transthyretin amyloidosis treatment market revenue, by region
• Fig. 43 Regional marketplace: Key takeaways
• Fig. 44 Regional marketplace: Key takeaways
• Fig. 45 North America transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
• Fig. 46 U.S. country dynamics
• Fig. 47 U.S. transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
• Fig. 48 Canada country dynamics
• Fig. 49 Canada transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
• Fig. 50 Mexico country dynamics
• Fig. 51 Mexico transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
• Fig. 52 Europe transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
• Fig. 53 UK country dynamics
• Fig. 54 UK transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
• Fig. 55 Germany country dynamics
• Fig. 56 Germany transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
• Fig. 57 France country dynamics
• Fig. 58 France transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
• Fig. 59 Italy country dynamics
• Fig. 60 Italy transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
• Fig. 61 Spain country dynamics
• Fig. 62 Spain transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
• Fig. 63 Norway country dynamics
• Fig. 64 Norway transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
• Fig. 65 Sweden country dynamics
• Fig. 66 Sweden transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
• Fig. 67 Denmark country dynamics
• Fig. 68 Denmark transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
• Fig. 69 Asia Pacific transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
• Fig. 70 Japan country dynamics
• Fig. 71 Japan transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
• Fig. 72 China country dynamics
• Fig. 73 China transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
• Fig. 74 India country dynamics
• Fig. 75 India transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
• Fig. 76 Australia country dynamics
• Fig. 77 Australia transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
• Fig. 78 South Korea country dynamics
• Fig. 79 South Korea transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
• Fig. 80 Thailand country dynamics
• Fig. 81 Thailand transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
• Fig. 82 Latin America transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
• Fig. 83 Brazil country dynamics
• Fig. 84 Brazil transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
• Fig. 85 Argentina country dynamics
• Fig. 86 Argentina transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
• Fig. 87 MEA transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
• Fig. 88 South Africa country dynamics
• Fig. 89 South Africa transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
• Fig. 90 Saudi Arabia country dynamics
• Fig. 91 Saudi Arabia transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
• Fig. 92 UAE country dynamics
• Fig. 93 UAE transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
• Fig. 94 Kuwait country dynamics
• Fig. 95 Kuwait transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
• Fig. 96 Company categorization
• Fig. 97 Company market position analysis
• Fig. 98 Strategic framework

Transthyretin Amyloidosis Treatment Market Growth & Trends:

The global transthyretin amyloidosis treatment market size is anticipated to reach USD 16.53 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 13.9% from 2025 to 2030. The transthyretin amyloidosis treatment market is mainly driven by the presence of supportive reimbursement programs and the growing African American population. The increasing African American population acted as a catalyst for the industry growth throughout the period owing to the high susceptibility to ATTR amyloidosis. The Val122Ile is the most prevalent mutation worldwide that leads to cardiomyopathy among the population specific to aged 65 years and above. Furthermore, this Val122Ile mutation is present in 3% to 4% of the African American population worldwide.

An increase in research activities for the development of novel diagnostic techniques and multidisciplinary therapeutic approaches is expected to lead to an increased survival rate and a more favorable prognosis of transthyretin amyloidosis. For instance, in November 2019, the Amyloidosis Research Consortium developed a disease-specific patient-reported outcome (PRO) tool to understand and measure the impact of transthyretin amyloidosis from the patient perspective. An introduction of such a tool will boost the research in developing a new target-specific drug by understanding disease complexity and patients' need, thereby widening the opportunity in the transthyretin amyloidosis treatment market.

Strategic initiatives undertaken by major players such as creating awareness regarding the target conditions such as ATTR and the long-term benefits of available therapies are expected to fuel industry growth. For instance, in 2019, Pfizer, Inc., in collaboration with the World Heart Federation, started the "Heart Hero" campaign. Under this campaign, Pfizer, Inc. provides educational information and resources related to ATTR-CM to patients and physicians. Such campaigns are expected to boost the early diagnosis of the disease and increase the treatment rate over time.

The movement undertaken by key players to provide free-of-cost medicine under their CSR activities is also projected to fuel market growth. For instance, the Pfizer Patient Assistance Program provides Pfizer medicines such as VYNDAMAX free of cost to eligible patients. People diagnosed with amyloidosis can take advantage of such programs by enrolling at the Vandalink platform. Such programs are expected to encourage physicians to prescribe this drug to a patient as drug therapy in transthyretin amyloidosis patients.

Transthyretin Amyloidosis Treatment Market Report Highlights:

• By type, the ATTR-CM accounted for a leading share in 2024 owing to the high prevalence of the disease and the rising geriatric population. The ATTR-PN is expected to exhibit the fastest growth rate throughout the forecast period. The segment growth is attributed to the presence of a strong pipeline
• By therapy, the targeted therapy segment grabbed a dominant share in 2024 owing to the worldwide approval of the therapies and the growing prescription rate for the treatment of ATTR-CM
• By disease type, the hereditary transthyretin amyloidosis segment dominated the market in 2024 owing to growing strategic alliances among various pharmaceutical companies aiming toward drug development along with growing pipeline drugs
• By distribution channel, the hospital pharmacies captured the largest share in 2024 as most of the hospitals are working toward the diagnosis, research, and treatment of transthyretin amyloidosis
• North America region held the largest share in 2024 owing to the increasing novel drug prescription, proper reimbursement policies, and higher treatment rates in the region
• The MEA region is expected to exhibit the fastest growth rate throughout the forecast period. The segment growth is attributed to the increasing incidence of ATTR amyloidosis

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Therapy
  • 1.2.2. Type
  • 1.2.3. Disease
  • 1.2.4. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Transthyretin Amyloidosis Treatment Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Transthyretin Amyloidosis Treatment Market: Therapy Business Analysis

• 4.1. Therapy Market Share, 2024 & 2030
• 4.2. Therapy Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
• 4.4. Targeted Therapy
  • 4.4.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
  • 4.4.2. Vyndaqel/ Vyndamax
    • 4.4.2.1. Vyndaqel/ Vyndamax Market, 2018 - 2030 (USD Million)
  • 4.4.3. Onpattro
    • 4.4.3.1. Onpattro Market, 2018 - 2030 (USD Million)
  • 4.4.4. Amvuttra
    • 4.4.4.1. Amvuttra Market, 2018 - 2030 (USD Million)
  • 4.4.5. Tegsedi
    • 4.4.5.1. Tegsedi Market, 2018 - 2030 (USD Million)
  • 4.4.6. Wainua
    • 4.4.6.1. Wainua Market, 2018 - 2030 (USD Million)
• 4.5. Supportive Therapy
  • 4.5.1. Supportive Therapy Market, 2018 - 2030 (USD Million)
• 4.6. Pipeline Therapy
  • 4.6.1. Pipeline Therapy Market, 2018 - 2030 (USD Million)

Chapter 5. Transthyretin Amyloidosis Treatment Market: Type Business Analysis

• 5.1. Type Market Share, 2024 & 2030
• 5.2. Type Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 5.4. ATTR with Polyneuropathy (ATTR-PN)
  • 5.4.1. ATTR with Polyneuropathy (ATTR-PN) Market, 2018 - 2030 (USD Million)
• 5.5. ATTR with Cardiomyopathy (ATTR-CM)
  • 5.5.1. ATTR with Cardiomyopathy (ATTR-CM) Market, 2018 - 2030 (USD Million)

Chapter 6. Transthyretin Amyloidosis Treatment Market: Disease Business Analysis

• 6.1. Disease Market Share, 2024 & 2030
• 6.2. Disease Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Disease, 2018 to 2030 (USD Million)
• 6.4. Hereditary Transthyretin Amyloidosis
  • 6.4.1. Hereditary Transthyretin Amyloidosis Market, 2018 - 2030 (USD Million)
  • 6.4.2. Polyneuropathy
    • 6.4.2.1. Polyneuropathy Market, 2018 - 2030 (USD Million)
  • 6.4.3. Cardiomyopathy
    • 6.4.3.1. Cardiomyopathy Market, 2018 - 2030 (USD Million)
  • 6.4.4. Mixed Type
    • 6.4.4.1. Mixed Type Market, 2018 - 2030 (USD Million)
• 6.5. Wild Type Amyloidosis
  • 6.5.1. Wild Type Amyloidosis Market, 2018 - 2030 (USD Million)

Chapter 7. Transthyretin Amyloidosis Treatment Market: Distribution Channel Business Analysis

• 7.1. Distribution Channel Market Share, 2024 & 2030
• 7.2. Distribution Channel Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 7.4. Hospital Pharmacies
  • 7.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
• 7.5. Specialty Pharmacies
  • 7.5.1. Specialty Pharmacies Market, 2018 - 2030 (USD Million)
• 7.6. Retail Pharmacies
  • 7.6.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
• 7.7. Online Pharmacies
  • 7.7.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 8. Transthyretin Amyloidosis Treatment Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.4. North America
  • 8.4.1. North America Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Regulatory Framework
    • 8.4.2.3. Competitive Insights
    • 8.4.2.4. U.S. Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Regulatory Framework
    • 8.4.3.3. Competitive Insights
    • 8.4.3.4. Canada Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Regulatory Framework
    • 8.4.4.3. Competitive Insights
    • 8.4.4.4. Mexico Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Regulatory Framework
    • 8.5.2.3. Competitive Insights
    • 8.5.2.4. UK Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Regulatory Framework
    • 8.5.3.3. Competitive Insights
    • 8.5.3.4. Germany Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Regulatory Framework
    • 8.5.4.3. Competitive Insights
    • 8.5.4.4. France Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Regulatory Framework
    • 8.5.5.3. Competitive Insights
    • 8.5.5.4. Italy Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Regulatory Framework
    • 8.5.6.3. Competitive Insights
    • 8.5.6.4. Spain Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.7. Norway
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Regulatory Framework
    • 8.5.7.3. Competitive Insights
    • 8.5.7.4. Norway Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.8. Denmark
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Regulatory Framework
    • 8.5.8.3. Competitive Insights
    • 8.5.8.4. Denmark Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5.9. Sweden
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Regulatory Framework
    • 8.5.9.3. Competitive Insights
    • 8.5.9.4. Sweden Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Regulatory Framework
    • 8.6.2.3. Competitive Insights
    • 8.6.2.4. Japan Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Regulatory Framework
    • 8.6.3.3. Competitive Insights
    • 8.6.3.4. China Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Regulatory Framework
    • 8.6.4.3. Competitive Insights
    • 8.6.4.4. India Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.5. South Korea
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Regulatory Framework
    • 8.6.5.3. Competitive Insights
    • 8.6.5.4. South Korea Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.6. Australia
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Regulatory Framework
    • 8.6.6.3. Competitive Insights
    • 8.6.6.4. Australia Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Regulatory Framework
    • 8.6.7.3. Competitive Insights
    • 8.6.7.4. Thailand Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Regulatory Framework
    • 8.7.2.3. Competitive Insights
    • 8.7.2.4. Brazil Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Regulatory Framework
    • 8.7.3.3. Competitive Insights
    • 8.7.3.4. Argentina Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.8. MEA
  • 8.8.1. MEA Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Regulatory Framework
    • 8.8.2.3. Competitive Insights
    • 8.8.2.4. South Africa Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Regulatory Framework
    • 8.8.3.3. Competitive Insights
    • 8.8.3.4. Saudi Arabia Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Regulatory Framework
    • 8.8.4.3. Competitive Insights
    • 8.8.4.4. UAE Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Regulatory Framework
    • 8.8.5.3. Competitive Insights
    • 8.8.5.4. Kuwait Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. Pfizer Inc.
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. Alnylam Pharmaceuticals, Inc.
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Ionis Pharmaceuticals
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. AstraZeneca
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Akcea Therapeutics
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. BridgeBio Inc.
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. Intellia Therapeutics, Inc.
    • 9.5.7.1. Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. SOM BIOTECH
    • 9.5.8.1. Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Oncopeptides AB
    • 9.5.9.1. Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. Takeda Pharmaceutical Company Limited
    • 9.5.10.1. Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Strategic Initiatives